Lexicon Pharma (LXRX) Announces Sale of XERMELO for $159 Million
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St futures rise as AI stocks gain, oil prices slide
- Oil prices slide to 11-day low on hopes of US-Iran diplomacy, Saudi exports
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Anthropic and Accenture partner on embedded AI safety evaluation
Lexicon Pharma (LXRX) to Resume Trading at 7:45 a.m.
July 30, 2020 7:42 AM EDTLexicon Pharma (NASDAQ: LXRX) to Resume Trading at 7:45 a.m.
... MoreLexicon Pharma (LXRX) Realigns Business Around Research and Development Assets, with Focus on Phase 2 LX9211 Neuropathic Pain Program
July 30, 2020 7:42 AM EDTLexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that it is realigning its business around its research and development assets, with a focus on its LX9211 neuropathic pain program, now in Phase 2 clinical development. In that regard:
Initiation of Phase 2 Clinical Development of LX9211. Lexicon has initiated patient screening in RELIEF-DPN-1, a Phase 2 randomized, placebo-controlled,... More
Lexicon Pharma (LXRX) Misses Q2 EPS by 4c, Revenues Beat
July 30, 2020 7:28 AM EDTLexicon Pharma (NASDAQ: LXRX) reported Q2 EPS of ($0.65), $0.04 worse than the analyst estimate of ($0.61). Revenue for the quarter came in at $9.2 million versus the consensus estimate of $8.83... More
